Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.

research_design_and_methods

The STEP TEENS phase 3a randomized study in adolescents (aged 12 to <18 years) with obesity demonstrated that once-weekly subcutaneous semaglutide 2.4 mg provided a significantly greater percentage reduction in BMI than placebo at week 68 (estimated difference -16.7 percentage points; P = 0.0001).

STEP TEENS第3a阶段的随机研究在12至<18岁的肥胖青少年中显示，每周一次皮下注射2.4毫克Semaglutide在第68周时与安慰剂相比，显著降低了更多的体重指数百分比（估计差异为-16.7个百分点；P = 0.0001）。

This analysis investigated changes in insulin sensitivity and cardiometabolic risk factors from baseline to week 68.

本分析研究了从基线到第68周胰岛素敏感性和心脏代谢风险因素的变化。

Results

Overall, 193 participants without type 2 diabetes were included in the analysis.

总体而言，分析中包括了193名未患有2型糖尿病的参与者。

Participants receiving semaglutide 2.4 mg (n = 129) compared with those receiving placebo (n = 64) had greater reductions from baseline in fasting serum insulin (-33.6% vs. -10.1%; P = 0.0012), homeostatic model assessment for insulin resistance (HOMA-IR) score (-35.0% vs. -5.3%; P = 0.0002), glycemic measures (glycated hemoglobin: P < 0.0001; fasting plasma glucose: P = 0.0181), alanine aminotransferase (ALT; -17.9% vs. -3.3%; P = 0.0232), waist-to-height ratio (P < 0.0001), triglycerides (P < 0.0001), LDL cholesterol (P = 0.0105), and total cholesterol (P < 0.0001).

接受semaglutide 2.4 mg的参与者(n = 129)与接受安慰剂的参与者(n = 64)相比，从基线开始在空腹血清胰岛素(-33.6% vs. -10.1%; P = 0.0012)、胰岛素抵抗的稳态模型评估(HOMA-IR)分数(-35.0% vs. -5.3%; P = 0.0002)、血糖指标(糖化血红蛋白: P < 0.0001; 空腹血浆葡萄糖: P = 0.0181)、丙氨酸氨基转移酶(ALT; -17.9% vs. -3.3%; P = 0.0232)、腰高比(P < 0.0001)、甘油三酯(P < 0.0001)、低密度脂蛋白胆固醇(P = 0.0105)和总胆固醇(P < 0.0001)方面有更大的降低。

Moreover, greater improvements in insulin sensitivity, glycemic measures, and cardiometabolic risk factors were seen in semaglutide 2.4 mg recipients with BMI reductions of ≥20% versus <20%.

此外，与BMI降低<20%的semaglutide 2.4 mg接受者相比，BMI降低≥20%的接受者在胰岛素敏感性、血糖指标和心血管代谢风险因素方面显示出更大的改善。

Conclusions

These novel data support semaglutide 2.4 mg as an efficacious obesity treatment in adolescents with obesity and advance its application by showing associated improvements in insulin sensitivity, glycemic measures, ALT, and other cardiometabolic risk factors.

这些新的数据支持将2.4毫克司美格鲁肽作为青少年肥胖治疗的有效药物，并通过显示与之相关的胰岛素敏感性、血糖指标、ALT和其他心血管代谢风险因素的改善，推进其应用。